Payment overview · 2025
General Payments
$1,114.67
70 reported records · 19 companies
Healthcare provider profile · identity verified
Gloria J Brelage, MD
Allopathic & Osteopathic Physicians|Family Medicine · BATESVILLE, IN · NPI 1063681021
Verified facts
What the public records show
CMS Open Payments records show Gloria J Brelage, MD received $1,114.67 in general payments during 2025 across 70 reported records.
Vanda Pharmaceuticals Inc. accounted for 19.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 29 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Ozempic.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Symbicort by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 49 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $219.89 | 19.7% | 14 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $158.16 | 14.2% | 14 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $100.90 | 9.1% | 5 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $99.58 | 8.9% | 6 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $92.68 | 8.3% | 6 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $60.21 | 5.4% | 3 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $54.29 | 4.9% | 3 | 2025 |
| Corium, LLC | Unresolved — no canonical attribution shown | $47.90 | 4.3% | 3 | 2025 |
| Biogen, Inc. | Unresolved — no canonical attribution shown | $46.31 | 4.2% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $45.20 | 4.1% | 3 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $33.86 | 3.0% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $32.27 | 2.9% | 2 | 2025 |
| Daiichi Sankyo Inc. | Unresolved — no canonical attribution shown | $24.63 | 2.2% | 1 | 2025 |
| Collegium Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $18.94 | 1.7% | 1 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $18.45 | 1.7% | 1 | 2025 |
| ABIOMED | Unresolved — no canonical attribution shown | $15.73 | 1.4% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $15.63 | 1.4% | 1 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $15.37 | 1.4% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $14.67 | 1.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,043.45 | 64 |
| Education | $71.22 | 6 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $219.89 | 14 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $112.50 | 11 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $100.90 | 5 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $92.68 | 6 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $76.91 | 5 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $75.34 | 8 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $60.21 | 3 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $54.29 | 3 | 2025 |
Source payment records
|
|||||
| Azstarys Normalized: azstarys |
Drug | Corium, LLC | $47.90 | 3 | 2025 |
Source payment records
|
|||||
| ZURZUVAE Normalized: zurzuvae |
Drug | Biogen, Inc. | $46.31 | 2 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $45.66 | 3 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $45.66 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $45.40 | 3 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $37.16 | 3 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $33.86 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $32.27 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $32.27 | 2 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $29.09 | 2 | 2025 |
Source payment records
|
|||||
| INJECTAFER Normalized: injectafer |
Drug | Daiichi Sankyo Inc. | $24.63 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $22.67 | 1 | 2025 |
Source payment records
|
|||||
| Jornay PM Normalized: jornay pm |
Drug | Collegium Pharmaceutical, Inc. | $18.94 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $18.53 | 1 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $18.45 | 1 | 2025 |
Source payment records
|
|||||
| PENBRAYA Normalized: penbraya |
Biological | PFIZER INC. | $16.57 | 1 | 2025 |
Source payment records
|
|||||
| TRUMENBA Normalized: trumenba |
Biological | PFIZER INC. | $15.98 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $15.63 | 1 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $15.37 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $14.67 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $14.67 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 53 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 49 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
49 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
53 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 381 | 87 |
| Lisinopril | Lisinopril | 257 | 63 |
| Omeprazole | Omeprazole | 210 | 50 |
| Levothyroxine Sodium | Levothyroxine Sodium | 205 | 48 |
| Metformin Hcl | Metformin Hcl | 187 | 38 |
| Hydrochlorothiazide | Hydrochlorothiazide | 184 | 49 |
| Amlodipine Besylate | Amlodipine Besylate | 174 | 44 |
| Furosemide | Furosemide | 138 | 30 |
| Simvastatin | Simvastatin | 119 | 30 |
| Prednisone | Prednisone | 108 | 52 |
| Gabapentin | Gabapentin | 98 | 25 |
| Montelukast Sodium | Montelukast Sodium | 94 | 26 |
| Pantoprazole Sodium | Pantoprazole Sodium | 90 | 23 |
| Alendronate Sodium | Alendronate Sodium | 87 | 21 |
| Losartan Potassium | Losartan Potassium | 84 | 16 |
| Trazodone Hcl | Trazodone Hcl | 81 | 14 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 76 | 11 |
| Metoprolol Succinate | Metoprolol Succinate | 74 | 22 |
| Metoprolol Tartrate | Metoprolol Tartrate | 70 | 18 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 60 | 17 |
| Duloxetine Hcl | Duloxetine Hcl | 59 | 11 |
| Sertraline Hcl | Sertraline Hcl | 59 | 15 |
| Alprazolam | Alprazolam | 55 | suppressed |
| Atenolol | Atenolol | 55 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 55 | 17 |
| Eliquis | Apixaban | 53 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 52 | 17 |
| Ozempic | Semaglutide | 49 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 48 | 13 |
| Fluticasone Propionate | Fluticasone Propionate | 48 | 17 |
| Celecoxib | Celecoxib | 47 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 47 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 47 | suppressed |
| Glimepiride | Glimepiride | 46 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 44 | 12 |
| Paroxetine Hcl | Paroxetine Hcl | 41 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 40 | 11 |
| Pravastatin Sodium | Pravastatin Sodium | 40 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 38 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 38 | 21 |
| Xarelto | Rivaroxaban | 38 | suppressed |
| Azithromycin | Azithromycin | 37 | 30 |
| Metformin Hcl Er | Metformin Hcl | 37 | suppressed |
| Potassium Chloride | Potassium Chloride | 36 | suppressed |
| Meloxicam | Meloxicam | 35 | suppressed |
| Carvedilol | Carvedilol | 34 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 34 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 34 | suppressed |
| Lorazepam | Lorazepam | 32 | suppressed |
| Glipizide Er | Glipizide | 31 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 31 | suppressed |
| Lovastatin | Lovastatin | 30 | suppressed |
| Spironolactone | Spironolactone | 29 | suppressed |
| Famotidine | Famotidine | 28 | suppressed |
| Allopurinol | Allopurinol | 27 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 27 | 19 |
| Donepezil Hcl | Donepezil Hcl | 27 | suppressed |
| Jardiance | Empagliflozin | 27 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 27 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 27 | suppressed |
| Ramipril | Ramipril | 26 | suppressed |
| Cephalexin | Cephalexin | 23 | 19 |
| Methocarbamol | Methocarbamol | 23 | suppressed |
| Pregabalin | Pregabalin | 23 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 23 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 23 | 16 |
| Cefdinir | Cefdinir | 22 | 18 |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 22 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 22 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 21 | suppressed |
| Chlorthalidone | Chlorthalidone | 21 | suppressed |
| Diazepam | Diazepam | 21 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 21 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 21 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 20 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 19 | suppressed |
| Ezetimibe | Ezetimibe | 19 | suppressed |
| Fluconazole | Fluconazole | 19 | 12 |
| Ibuprofen | Ibuprofen | 19 | suppressed |
| Levetiracetam | Levetiracetam | 19 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 19 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 18 | suppressed |
| Fentanyl | Fentanyl | 17 | suppressed |
| Myrbetriq | Mirabegron | 16 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 16 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 15 | suppressed |
| Lansoprazole | Lansoprazole | 15 | suppressed |
| Trulicity | Dulaglutide | 15 | suppressed |
| Vascepa | Icosapent Ethyl | 15 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 14 | suppressed |
| Januvia | Sitagliptin Phosphate | 14 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 14 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 14 | suppressed |
| Fenofibrate | Fenofibrate | 13 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 13 | suppressed |
| Indomethacin | Indomethacin | 13 | suppressed |
| Naproxen | Naproxen | 13 | suppressed |
| Aripiprazole | Aripiprazole | 12 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 12 | suppressed |
| Diclofenac Sodium Er | Diclofenac Sodium | 12 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 12 | suppressed |
| Ec-Naproxen | Naproxen | 12 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 12 | suppressed |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 12 | suppressed |
| Latanoprost | Latanoprost | 12 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 12 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 12 | suppressed |
| Olanzapine | Olanzapine | 12 | suppressed |
| Synthroid | Levothyroxine Sodium | 12 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 12 | suppressed |
| Valsartan | Valsartan | 12 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 11 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 11 | suppressed |
| Entresto | Sacubitril/Valsartan | 11 | suppressed |
| Estradiol | Estradiol | 11 | suppressed |
| Flurbiprofen | Flurbiprofen | 11 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 11 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 11 | suppressed |
| Mupirocin | Mupirocin | 11 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 11 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,114.67 · 70 records | Vanda Pharmaceuticals Inc. | ABRYSVO, AREXVY, Azstarys, COMIRNATY, Cologuard Collection Kit, ELIQUIS, FANAPT, FREESTYLE LIBRE 3, INJECTAFER, INSPIRE, Jornay PM, Kerendia, MOUNJARO, NURTEC ODT, OTEZLA, Ohtuvayre, Ozempic, PENBRAYA, PREVNAR 20, REPATHA, Rybelsus, TRELEGY ELLIPTA, TRINTELLIX, TRUMENBA, Veozah, Wegovy, ZAVZPRET, ZEPBOUND, ZURZUVAE | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Astellas Pharma US Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error